Membrane-permeable NFAT inhibitory peptide

• US 20070093427A1
• Filed: 12/05/2006
• Published: 04/26/2007
• Est. Priority Date: 02/28/2002
• Status: Active Grant

• Current Assignee: Japan Science And Technology Agency, Matsui Hideki, Matsushita Masayuka
• Original Assignee: Japan Science And Technology Agency, Matsui Hideki, Matsushita Masayuka
• Inventors: Matsushita, Masayuki, Matsui, Hideki
• Granted Patent: US 7,659,249 B2
• Time in Patent Office: Days
• US Class Current: 424/278.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C07K 2319/10 containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Abstract

The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.

Claims

1. A therapeutic method, comprising the step of:

administering a peptide compound comprising 9 to 13 residues of arginine and the amino acid sequence of SEQ ID NO;

1, to a patient at a level that produces immunosuppression in the patient.

2. The therapeutic method of claim 1, wherein said peptide compound comprises 11 residues of arginine.

3. The therapeutic method of claim 1, wherein the compound is administered at a dosage in the range of 1 to 10 mg/kg.

4. The therapeutic method of claim 2, wherein the compound is administered at a dosage in the range of 1 to 10 mg/kg.

6. The therapeutic method of claim 1, wherein said peptide comprises 11 residues of arginine.

8. The therapeutic method of claim 6, wherein the compound is administered at a dosage in the range of 0.1 to 2 mg/kg.

5. A therapeutic method, comprising the step of:

administering a peptide compound comprising 9 to 13 residues of arginine and the amino acid sequence of SEQ ID NO;

1, to a patient at a level that suppresses cardiac hypertrophy in the patient.

7. The therapeutic method of claim 5, wherein the compound is administered at a dosage in the range of 0.1 to 2 mg/kg.